We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Accelerating Cancer Cures aims to train young clinical investigators

Accelerating Cancer Cures aims to train young clinical investigators

June 24, 2011
CenterWatch Staff

A number of leading pharmaceutical companies are supporting a collaborative initiative that aims to replenish the stock of young clinical investigators working in oncology and promote translational research spanning academia and industry, PharmaTimes reported.

Accelerating Cancer Cures is a $25 million program that will fund and train more than 50 physician-scientists in clinical oncology research. More than $5 million to date has been pledged toward the fund by biopharmaceutical companies including Eli Lilly, Celgene, Merck, Millennium and Pfizer, as well as industry association The Pharmaceutical Research and Manufacturers of America (PhRMA).

The initiative builds on the existing Clinical Investigator Award program run by the Damon Runyon Cancer Research Foundation. The new funding from Accelerating Cancer Cures will increase the number of Clinical Investigator Awards to 10 a year.

At its recent spring 2011 Clinical Investigator Award Committee review, the foundation granted a total of $3.45 million to five early-career physician-scientists conducting patient-oriented cancer research, and to four Damon Runyon Clinical Investigators approaching the end of their original awards and needing extra time and funding to complete promising research or initiate/continue a clinical trial.

The new program has a marked emphasis on translational research and working with industry. Accelerating Cancer Cures will fund the work of early career physician-scientists to address the “critical” shortage of young scientists entering the clinical oncology research field in the U.S., and provide these investigators with access to senior oncology executives and leaders in academic cancer research to help them translate discoveries into therapies. It aims to create opportunities for the investigators to collaborate with pharmaceutical and biotechnology companies and to learn about industry research as visiting scientists. It also plans to foster collaboration between researchers by hosting an annual translational research summit bringing together young scientists and leaders from industry and academia.

“Accelerating Cancer Cures is an opportunity to build a new generation of leaders in clinical cancer research that not only produce exceptional science, but can work with industry to bring new treatments to patients,” said John Castellani, president and CEO of PhRMA.

 

United States Study Conduct

Upcoming Events

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

  • China-360x240

    U.S. Tops List of Trial Startups With China Making Progress in Phase 1

  • Phoneapp-360x240

    Device Apps Present Unique Risks in Trials

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing